|
1
|
Dinh P, Sotiriou C and Piccart MJ: The evolution of treatment strategies: Aiming at the target. Breast. 16 (Suppl 2):S10–S16. 2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW and Carey LA: Poly(ADP-Ribose) polymerase inhibition: ‘targeted’ therapy for triple-negative breast cancer. Clin Cancer Res. 16:4702–4710. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2:1036–1047. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Neergheen VS, Bahorun T, Taylor EW, Jen LS and Aruoma OI: Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemo-prevention. Toxicology. 278:229–241. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ye L, Jia Y, Ji KE, Sanders AJ, Xue K, Ji J, Mason MD and Jiang WG: Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis. Oncol Lett. 10:1240–1250. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Telang N, Li G, Katdare M, Sepkovic D, Bradlow L and Wong G: Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function. Oncol Lett. 12:3949–3957. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Telang NT, Li G, Katdare M, Sepkovic DW, Bradlow HL and Wong GYC: The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer. Oncol Lett. 13:2477–2482. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Telang N, Nair HB and Wong GYC: Efficacy of Dipsacus asperoides (DA) in a model for triple negative breast cancer. Cancer Res. 77 (Suppl 4):Abstract nr P4-13-04. 2017.
|
|
10
|
Telang NT, Nair HB and Wong GYC: Growth inhibitory efficacy of Cornus officinalis in a cell culture model for triple-negative breast cancer. Oncol Lett. 17:5261–5266. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bosco EE and Knudsen ES: RB in breast cancer: At the crossroads of tumorigenesis and treatment. Cell Cycle. 6:667–671. 2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe J-P, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, et al: The expression patterns of ER, PR, HER-2, CK5/6, EGFR, Ki 67, and AR by immune-histochemical analysis in breast cancer cell lines. Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBIErratum in: Breast Cancer (Auckl) 12: 1178223418806626, 2018.
|
|
14
|
Khushboo PS, Jadhav VM, Kadam VJ and Sathe NS: Psoralea corylifolia Linn. - ‘Kushtanashini’. Pharmacogn Rev. 4:69–76. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Telang N: Anti-proliferative and pro-apoptotic effects of rosemary and constituent terpenoids in a model for the HER-2-enriched molecular subtype of clinical breast cancer. Oncol Lett. 16:5489–5497. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Burkhart DL and Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 11:558–572. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sherr CJ and Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhang X, Zhao W, Wang Y, Lu J and Chen X: The chemical constituents and bioactivities of Psoralia corylifolia Linn.: A Review. Am J Chin Med. 44:35–60. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shi J, Chen Y, Chen W, Tang C, Zhang H, Chen Y, Yang X, Xu Z, Wei J and Chen J: Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells. J Cell Mol Med. 22:5220–5230. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Li Y, Qin X, Li P, Zhang H, Lin T, Miao Z and Ma S: Isobavachalcone isolated from Psoralia corylifolia inhibits cell proliferation and induces apoptosis via inhibiting AKT/GSK-3β/β-catenin pathway. Drug Des Devel Ther. 13:1449–1460. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Park GH, Sung JH, Song HM and Jeong JB: Anti-cancer activity of Psoralea fructus through the downregulation of cyclin D1 and CDK4 in human colorectal cancer cells. BMC Complement Altern Med. 16(373)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Rajan V, Tripathi J, Variyar P and Pandey BN: Mechanism of cytotoxicity by Psoralea corylifolia extract in human breast carcinoma cells. J Environ Pathol Toxicol Oncol. 33:265–277. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang X, Cheng K, Han Y, Zhang G, Dong J, Cui Y and Yang Z: Effect of Psoralen as an anti-tumor agent in human breast cancer MCF-7/ADR cells. Biol Pharm Bull. 39:815–822. 2016.PubMed/NCBI View Article : Google Scholar
|
